Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 3/20 | 0.78 |
| ▸ | MCHR1 | Q99705 | 8/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.45 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.44 |
| ▸ | HTR3B | O95264 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27634523 | 1.00 | P2RX7 (0.78) | P2RX7MCHR1HTR2CMCHR2HTR3E | |
| Hydrochloric Acid SCHEMBL5131271 | 0.99 | P2RX7 (0.77) | P2RX7MCHR1HTR2CMCHR2HTR3E | |
| SCHEMBL5131982 | 0.93 | P2RX7 (0.73) | P2RX7MCHR1HTR2CMCHR2HTR3E | |
| SCHEMBL27634382 | 0.93 | P2RX7 (0.73) | P2RX7MCHR1HTR2CMCHR2HTR3E | |
| SCHEMBL5123982 | 0.88 | P2RX7 (1.00) | P2RX7MCHR1HTR2CMCHR2HTR3E | |
| Hydrochloric Acid SCHEMBL5128207 | 0.87 | P2RX7 (0.98) | P2RX7MCHR1HTR2CMCHR2HTR3E | |
| SCHEMBL5125437 | 0.85 | P2RX7 (0.80) | P2RX7MCHR1HTR2CMCHR2HTR3E | |
| SCHEMBL27634467 | 0.85 | P2RX7 (0.80) | P2RX7MCHR1HTR2CMCHR2HTR3E | |
| Hydrochloric Acid SCHEMBL5131649 | 0.85 | P2RX7 (0.78) | P2RX7MCHR1HTR2CMCHR2HTR3E | |
| SCHEMBL5128500 | 0.81 | P2RX7 (0.70) | P2RX7MCHR1HTR2CMCHR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058293-A1 | Quinoline Derivates and Their Use in Therapy | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | claimed |
| CN-1829694-A | quinoline derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2006-09-06 | — | — | CN | claimed |
| EP-1651610-A1 | QUINOLINE DERIVATES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2006-05-03 | — | — | EP | claimed |
| WO-2005009968-A1 | QUINOLINE DERIVATES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | WO | claimed |
| US-20080058293-A1 | Quinoline Derivates and Their Use in Therapy | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| CN-1829694-A | quinoline derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2006-09-06 | — | — | CN | disclosed |
| EP-1651610-A1 | QUINOLINE DERIVATES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005009968-A1 | QUINOLINE DERIVATES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058293-A1 | Quinoline Derivates and Their Use in Therapy | NQO2, RECQL, CHRM1 | P2RX7 91/4885MCHR1 1327/4885HTR2C 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.